STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target (Q42653850)

4 November 2017

STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target (English)

1 reference

4 November 2017

1 reference

Chung N

1

1 reference

4 November 2017

Cho SY

2

1 reference

4 November 2017

Choi DH

3

1 reference

4 November 2017

Zhu JR

4

1 reference

4 November 2017

Lee K

5

1 reference

4 November 2017

Lee PY

6

1 reference

4 November 2017

Lee SH

7

1 reference

4 November 2017

Lee S

8

1 reference

4 November 2017

Wang JJ

9

1 reference

4 November 2017

Yin WH

10

1 reference

4 November 2017

Young MS

11

1 reference

4 November 2017

Koh KK

12

1 reference

4 November 2017

Son JW

13

1 reference

4 November 2017

Sangwatanaroj S

14

1 reference

4 November 2017

Panchavinnin P

15

1 reference

4 November 2017

Phankingthongkum R

16

1 reference

4 November 2017

Cai NS

17

1 reference

4 November 2017

Fan WF

18

1 reference

4 November 2017

1 June 2001

1 reference

4 November 2017

Clinical Therapeutics

1 reference

4 November 2017

23

1 reference

4 November 2017

6

1 reference

4 November 2017

858-870

1 reference

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Persistence of use of lipid-lowering medications: a cross-national study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980074-6

7 January 2021

10.1016/S0149-2918(01)80074-6

Identifiers

DOI

1 reference

4 November 2017

1 reference